Business Context and Reporting Period
Company: Wound Management Technologies, Inc. (Note: Metadata lists "Sanara Medtech Inc.", but the filing identifies the registrant as Wound Management Technologies, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: The Company distributes FDA-cleared collagen-based wound care products (CellerateRx) for acute and chronic wounds. Operations include marketing, development, and distribution of medical devices. Manufacturing and warehousing are outsourced.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2009 | 9 Months Ended Sep 30, 2008 |
|---|---|---|
| Total Revenue | $229,644 | $215,484 |
| Cost of Revenue | $511,875 | $268,357 |
| Gross Profit (Loss) | $(282,231) | $(52,873) |
| Net Loss | $(1,069,380) | $(928,228) |
| Cash and Equivalents (End of Period) | $6,068 | $6,387 |
| Total Assets | $4,934,524 | $151,714 |
| Total Liabilities | $1,606,632 | $472,971 |
| Stockholders' Equity | $3,327,892 | $(321,257) |
Liquidity & Debt: The Company holds minimal cash ($6,068). Current liabilities include $550,000 in notes payable to unrelated parties and $407,850 in notes payable to related parties. The Company has an accumulated deficit of $15,841,958.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 6.6% year-over-year for the nine-month period ($229,644 vs. $215,484).
- Gross Margin Deterioration: The Company moved from a gross loss of $52,873 in the prior period to a gross loss of $282,231. Cost of revenue more than doubled despite modest revenue growth.
- Balance Sheet Expansion: Total assets increased significantly from $151,714 to $4,934,524. This is primarily due to the acquisition of intangible assets (marketing contracts and patents) valued at approximately $4.7 million, largely paid for via stock issuance rather than cash.
- Equity Turnaround: Stockholders' equity shifted from a deficiency of $(321,257) to a positive balance of $3,327,892, driven by the capitalization of acquired intangible assets and stock issuances.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management explicitly states that conditions raise "substantial doubt" about the Company's ability to continue as a going concern. The Company relies on obtaining additional financing or equity capital to meet obligations for the next 12 months.
- Acquisitions:
- BioPharma: Acquired BioPharma Management Technologies, Inc. on Sept 17, 2009, issuing 4.5 million shares valued at $4,187,515 for marketing rights.
- Resorbable: Acquired a patent from Resorbable Orthopedic Products, LLC on Sept 29, 2009, issuing 500,000 shares valued at $462,715.
- Payroll Tax Delinquency: The Company is delinquent on federal payroll taxes. As of Sept 30, 2009, unpaid taxes totaled approximately $203,000, with estimated penalties and interest of $179,000.
- Debt Structure: The Company carries high-interest debt (18% per annum) from unrelated parties and 10% interest from related parties. A $100,000 promissory note was signed but remained unfunded as of the balance sheet date.
- Subsequent Events: On Nov 2, 2009, the Company entered a Letter of Intent to acquire assets from VirtualHealth Technologies, Inc., subject to definitive agreement.
Investor Verification Checklist
- Going Concern Status: Verify if the Company has secured the additional debt or equity financing required to sustain operations for the next 12 months.
- Payroll Tax Liability: Confirm the status of the $203,000 unpaid payroll tax liability and the $179,000 in penalties/interest with the IRS.
- Valuation of Intangibles: Assess the fair value and revenue-generating potential of the $4.7 million in intangible assets (BioPharma marketing rights and Resorbable patent) acquired via stock issuance.
- Debt Maturities: Review the repayment schedule for the $550,000 note due in January 2010 and the $407,850 related party notes.
- Revenue Quality: Analyze the sustainability of revenue growth given the significant increase in Cost of Revenue and the resulting gross loss.